All In Biotech

Drug Trial Radar · NCT01344447

Gadobutrol Enhanced MRA of the Supra-aortic Vessels

Multicenter, Open-label Study to Evaluate the Safety and Efficacy (by Blinded Reading) of Contrast-Enhanced Magnetic Resonance Angiography (MRA) After a Single Intravenous Injection of 0.1 mmol/kg Gadobutrol in Subjects With Known or Suspected Vascular Disease of the Supra-aortic Vessels

Last checked: Nov 19, 2026Latest source record: Jan 4, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

479

Actual

Start

May 12, 2011

Primary completion

May 28, 2014

Study completion May 28, 2014

Sponsor

Lead sponsor
BayerBayer (BAYRY)
Sponsor type
Industry
First posted
Apr 29, 2011

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Diagnostic
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Subjects referred for a routine CTA (computed tomography angiography) or MRA (magnetic resonance angiography) will be invited to participate in the study and subjects will be involved in the study for between 2 and 12 days. Two to three visits to the study doctor will be required. This study will compare the diagnostic results of Gadobutrol enhanced MRA images with MRA images taken without contrast agent using images from a CTA as the standard of reference, which may have been performed up to 60 days prior to enrolment. If a CTA has not been performed in this prior time period, a CTA is required for the study. MRA and CTA images will be collected for an independent review (blinded read).

Conditions

  • Carotid Stenosis

Interventions

  • Gadobutrol (Gadovist, BAY86-4875)Drug

    A single bolus injection of approx. 0.1mmol/kg

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Assessable Vascular Segments Using Gadobutrol-Enhanced MRA and Unenhanced MRATime frame: Images were taken pre-injection and post-injection
  2. Sensitivity for Detection of Clinically Significant Disease Using Gadobutrol-Enhanced MRA and Unenhanced MRATime frame: Images were taken pre-injection and post-injection
  3. Specificity for Exclusion of Clinically Significant Disease Using Gadobutrol-Enhanced MRA and Unenhanced MRATime frame: Images were taken pre-injection and post-injection
  4. Minimum Gadobutrol Performance for Sensitivity: Sensitivity > 50%Time frame: Images were taken pre-injection and post-injection
  5. Minimum Gadobutrol Performance for Specificity: Specificity > 50%Time frame: Images were taken pre-injection and post-injection

Locations

56 sites in 14 countries. Site status is shown where the registry gives one.

  • Site not named

    Tucson, Arizona

  • Site not named

    Jacksonville, Florida

  • Site not named

    Savannah, Georgia

  • Site not named

    Louisville, Kentucky

  • Site not named

    Baltimore, Maryland

  • Site not named

    Boston, Massachusetts

  • Site not named

    Ann Arbor, Michigan

  • Site not named

    Jackson, Mississippi

  • Site not named

    Rochester, New York

  • Site not named

    The Bronx, New York

  • Site not named

    Philadelphia, Pennsylvania

  • Site not named

    Providence, Rhode Island

  • Site not named

    Memphis, Tennessee

  • Site not named

    Seattle, Washington

  • Site not named

    Madison, Wisconsin

  • Site not named

    Adrogué, Buenos Aires, Argentina

  • Site not named

    Buenos Aires, Ciudad Auton. de Buenos Aires, Argentina

  • Site not named

    Buenos Aires, Ciudad Auton. de Buenos Aires, Argentina

  • Site not named

    New Lambton Heights, New South Wales, Australia

  • Site not named

    Clayton, Victoria, Australia

  • Site not named

    Parkville, Victoria, Australia

  • Site not named

    Vienna, Austria

  • Site not named

    Innsbruck, Tyrol, Austria

  • Site not named

    Shanghai, China

  • Site not named

    Shanghai, China

  • Site not named

    Brno, Czechia

  • Site not named

    Brest, France

  • Site not named

    Bron, France

  • Site not named

    Marseille, France

  • Site not named

    Paris, France

  • Site not named

    Paris, France

  • Site not named

    Karlsruhe, Baden-Wurttemberg, Germany

  • Site not named

    Augsburg, Bavaria, Germany

  • Site not named

    Erlangen, Bavaria, Germany

  • Site not named

    Münster, North Rhine-Westphalia, Germany

  • Site not named

    Jena, Thuringia, Germany

  • Site not named

    Aosta, Aosta Valley, Italy

  • Site not named

    Ferrara, Emilia-Romagna, Italy

  • Site not named

    Rome, Lazio, Italy

  • Site not named

    Catania, Sicily, Italy

Showing 40 of 56 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.